These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 22115327

  • 1. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States.
    Schabert VF, Watson C, Gandra SR, Goodman S, Fox KM, Harrison DJ.
    J Med Econ; 2012; 15(2):264-75. PubMed ID: 22115327
    [Abstract] [Full Text] [Related]

  • 2. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
    Bonafede MM, Gandra SR, Watson C, Princic N, Fox KM.
    Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
    Bonafede M, Joseph GJ, Princic N, Harrison DJ.
    J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA, Klingman D, Hazard E, Ray S.
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis.
    Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M.
    Curr Med Res Opin; 2008 Aug; 24(8):2229-40. PubMed ID: 18577308
    [Abstract] [Full Text] [Related]

  • 13. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
    Bonafede MM, Gandra SR, Fox KM, Wilson KL.
    J Med Econ; 2012 Aug; 15(4):635-43. PubMed ID: 22332705
    [Abstract] [Full Text] [Related]

  • 14. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
    Wu N, Lee YC, Shah N, Harrison DJ.
    Clin Ther; 2014 Aug 01; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
    [Abstract] [Full Text] [Related]

  • 15. Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan.
    Chastek B, Fox KM, Watson C, Gandra SR.
    Adv Ther; 2012 Aug 01; 29(8):691-7. PubMed ID: 22903239
    [Abstract] [Full Text] [Related]

  • 16. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
    Sauer BC, Teng CC, He T, Leng J, Lu CC, Walsh JA, Shah N, Harrison DJ, Tang DH, Cannon GW.
    J Med Econ; 2016 Aug 01; 19(1):34-43. PubMed ID: 26337538
    [Abstract] [Full Text] [Related]

  • 17. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X, Wendling D, Botteman MF, Carter JA, Rao S, Cifaldi M.
    J Med Econ; 2012 Aug 01; 15(6):1054-63. PubMed ID: 22563743
    [Abstract] [Full Text] [Related]

  • 18. Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data.
    Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M.
    Curr Med Res Opin; 2007 Aug 01; 23(8):1749-59. PubMed ID: 17588306
    [Abstract] [Full Text] [Related]

  • 19. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate.
    Harley CR, Frytak JR, Tandon N.
    Am J Manag Care; 2003 Oct 01; 9(6 Suppl):S136-43. PubMed ID: 14577718
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.